COMPUTER-AIDED DESIGN AND SYNTHESIS OF NOVEL DRUG CANDIDATES TARGETING CANCER-RELATED ENZYMES
Keywords:
computer-aided drug design; quinazoline; EGFR; VEGFR-2; kinase inhibitors; anticancer agents; molecular descriptors; molecular docking; medicinal chemistry.Abstract
Targeted inhibition of oncogenic protein kinases remains a central strategy in anticancer drug discovery. This study presents a computer-aided design framework for a small series of 4-anilino-6,7-dimethoxyquinazoline derivatives intended for dual compatibility with epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor 2 (VEGFR-2), two clinically validated cancer-related enzymes. Eight analogues (C1–C8) bearing para-substituted aniline groups were generated and assessed using molecular descriptors, drug-likeness criteria, structural-alert screening principles, and a transparent multi-parameter lead-prioritization score. A docking-ready protocol was formulated using EGFR L858R/T790M (PDB 4I22) and VEGFR-2 in complex with sorafenib (PDB 4ASD) as structural models. Molecular weight, cLogP, topological polar surface area, hydrogen-bond capacity, rotatable bonds, and quantitative estimate of drug-likeness were calculated for all candidates. The designed set occupied a compact drug-like chemical space, while halogen, cyano, trifluoromethyl, methoxy, and methyl substitutions modulated lipophilicity and polar surface area in predictable ways. The proposed synthetic route is based on nucleophilic aromatic substitution of a 4-chloroquinazoline intermediate with the corresponding aniline derivative. The results identify balanced candidates for subsequent docking, synthesis, kinase inhibition assays, and cancer-cell validation without presenting unperformed biological or docking values as experimental findings. The workflow provides a reproducible design–make–test framework for early-stage discovery of kinase-directed anticancer agents.
References
1. Uba, A. I. (2025). Computer-Aided Design of VEGFR-2 Inhibitors as Anticancer Agents: A Review. Journal of Molecular Recognition, 38(1), e3104. https://doi.org/10.1002/jmr.3104
2. Șandor, A., Ionuț, I., Marc, G., & Oniga, I. (2023). Structure–Activity Relationship Studies Based on Quinazoline Derivatives as EGFR Kinase Inhibitors (2017–Present). Pharmaceuticals, 16(4), 534.
3. Abdallah, A. E., Mabrouk, R. R., Al Ward, M. M. S., Eissa, S. I., Elkaeed, E. B., Mehany, A. B. M., et al. (2022). Synthesis, biological evaluation, and molecular docking of new series of antitumor and apoptosis inducers designed as VEGFR-2 inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 37(1), 573–591. https://doi.org/10.1080/14756366.2021.2017911
4. Mabrouk, R. R., Musa, A., Al Ward, M. M. S., Hussein, S., Aljohani, A. K. B., El-Zahabi, M. A., & Elwan, A. (2025). Design, synthesis, and cytotoxic evaluation of quinazoline-based derivatives as VEGFR-2 inhibitors: comparative study against EGFR kinase activity, induction of apoptosis, and molecular docking study. RSC Advances, 15, 29593–29612. https://doi.org/10.1039/D5RA03829D
5. Hao, S., Wang, J.-H., Hou, L., Liang, J.-W., Yan, J.-H., Niu, Y.-F., Li, X.-Y., Sun, Q., & Meng, F.-H. (2024). Design, synthesis and biological evaluation of novel quinazoline-derived EGFR/HER-2 dual-target inhibitors bearing a heterocyclic-containing tail as potential anti-tumor agents. Bioorganic Chemistry, 151, 107686. https://doi.org/10.1016/j.bioorg.2024.107686
6. Aref, M. M. A., Abdallah, A. E., Dahab, M. A., Mohamed, A. A., Celik, I., Bawazir, W. A., et al. (2026). Design, synthesis, anticancer evaluation, biological screening, and computational study of novel 6,7-dimethoxyquinazoline derivatives as VEGFR-2 inhibitors and apoptotic inducers. European Journal of Medicinal Chemistry, 301, 118187. https://doi.org/10.1016/j.ejmech.2025.118187
7. Haneen, D. S. A., Abdalha, A. A., Alkhatib, M. M., Kamal, M., Youssef, A. S. A., Abou-Elmagd, W. S. I., & Samir, S. S. (2025). Synthesis, comprehensive in silico studies, and cytotoxicity evaluation of novel quinazolinone derivatives as potential anticancer agents. Scientific Reports, 15, 23697. https://doi.org/10.1038/s41598-025-08062-7
8. Șandor, A., Crișan, O., Marc, G., Fizeșan, I., Ionuț, I., Moldovan, C., Stana, A., Oniga, I., Pîrnău, A., & Oniga, O. (2025). Rational Design and Synthesis of a Novel Series of Thiosemicarbazone-Containing Quinazoline Derivatives as Potential VEGFR2 Inhibitors. Pharmaceutics, 17(2), 260.
9. Long, H.-Z., Fu, M.-J., Ji, X.-Q., Liu, C.-J., Wang, B., Gao, Y., Liu, H.-M., Zheng, Y.-C., Liu, H.-M., & Dai, X.-J. (2026). Unveiling the power of quinazoline derivatives: a new frontier in targeted cancer therapy. Bioorganic & Medicinal Chemistry, 133, 118497. https://doi.org/10.1016/j.bmc.2025.118497
10. Eberhardt, J., Santos-Martins, D., Tillack, A. F., & Forli, S. (2021). AutoDock Vina 1.2.0: New Docking Methods, Expanded Force Field, and Python Bindings. Journal of Chemical Information and Modeling, 61(8), 3891–3898. https://doi.org/10.1021/acs.jcim.1c00203
11. Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 46(1–3), 3–26. https://doi.org/10.1016/S0169-409X(00)00129-0
12. Lipinski, C. A. (2016). Rule of five in 2015 and beyond: Target and ligand structural limitations, ligand chemistry structure and drug discovery project decisions. Advanced Drug Delivery Reviews, 101, 34–41. https://doi.org/10.1016/j.addr.2016.04.029
13. Bickerton, G. R., Paolini, G. V., Besnard, J., Muresan, S., & Hopkins, A. L. (2012). Quantifying the chemical beauty of drugs. Nature Chemistry, 4, 90–98.
14. Baell, J. B., & Holloway, G. A. (2010). New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. Journal of Medicinal Chemistry, 53(7), 2719–2740. https://doi.org/10.1021/jm901137j
15. Warren, G. L., Andrews, C. W., Capelli, A.-M., Clarke, B., LaLonde, J., Lambert, M. H., et al. (2006). A critical assessment of docking programs and scoring functions. Journal of Medicinal Chemistry, 49(20), 5912–5931. https://doi.org/10.1021/jm050362n
